BioLargo (BLGO) AI Stock Analysis

• Market Cap: $52.07M
• Dividend Yield: N/A
• Average Volume (3M): 373.54K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.24
• Revenue Growth: 22.97%
• EPS Growth: 17.32%
• Country: US
• Employees: 40
• Sector: Basic Materials
• Sector Strength: 57
• Industry: Chemicals
• EPS (TTM): N/A
• Shares Outstanding: 304,850,980
• 10 Day Avg. Volume: 307,982
• 30 Day Avg. Volume: 373,544
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 3.28
• Enterprise Value/Gross Profit: 7.53
• Enterprise Value/Ebitda: -10.41
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

BioLargo's score is primarily driven by financial performance challenges, including unprofitability and cash flow issues. Technical analysis indicates bearish momentum. However, positive corporate events highlight potential future growth opportunities, providing some optimism.

BioLargo Business Overview & Revenue Model

Company Description

BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

How the Company Makes Money

BioLargo makes money primarily through the commercial sale of its proprietary environmental and industrial products and services. Key revenue streams include sales from its Advanced Oxidation System (AOS) for water treatment, the CupriDyne Clean industrial odor control products, and its BioLargo Engineering, Science & Technologies division, which provides consulting and custom engineering services. Additionally, its medical technology segment, which includes products like the BioLargo Wound Care brand, contributes to revenue. The company also leverages strategic partnerships and licensing agreements to expand the reach of its technologies and products, enhancing its revenue potential.

BioLargo Financial Statement Overview

Summary

BioLargo has shown significant revenue growth, indicating market acceptance, but remains unprofitable with persistent net losses and negative cash flows. The balance sheet shows improved equity and reduced leverage, but liquidity risks remain due to negative operating cash flow.

Income Statement

BioLargo has demonstrated significant revenue growth, increasing from $1.86M in 2019 to $17.78M in 2024, showing a strong upward trajectory. However, the company remains unprofitable with consistent net losses, including a net loss of $2.40M in 2024. The gross profit margin has improved but remains volatile. EBIT and EBITDA margins remain negative, indicating operational challenges.

Balance Sheet

BioLargo's financial stability is supported by a strong equity position with a debt-to-equity ratio significantly improved over the years, now at 0.17. The equity ratio is healthy at 84.18%. However, the company has high leverage in earlier years and a history of negative net debt, indicating potential liquidity risks.

Cash Flow

Operating cash flow has been consistently negative, reflecting ongoing operational cash burn. Free cash flow growth has not been positive, and the free cash flow to net income ratio remains challenging. While financing activities have supported cash needs, sustained negative cash flows pose a risk to long-term financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.78M	12.23M	5.88M	2.53M	2.43M
Gross Profit	7.85M	6.15M	2.86M	1.10M	1.23M
EBITDA	-4.06M	-4.19M	-5.10M	-6.70M	-7.83M
Net Income	-2.40M	-3.50M	-4.50M	-7.38M	-10.47M
Balance Sheet
Total Assets	10.51M	8.21M	4.86M	3.02M	4.94M
Cash, Cash Equivalents and Short-Term Investments	3.55M	3.54M	1.85M	962.00K	716.00K
Total Debt	2.55M	1.70M	1.47M	1.13M	2.67M
Total Liabilities	4.46M	4.00M	2.85M	2.09M	5.18M
Stockholders Equity	8.85M	6.84M	4.88M	4.65M	3.86M
Cash Flow
Free Cash Flow	-4.44M	-2.84M	-3.03M	-3.97M	-4.18M
Operating Cash Flow	-3.21M	-2.37M	-2.76M	-3.94M	-4.15M
Investing Cash Flow	-1.32M	-478.00K	-271.00K	-34.00K	-123.00K
Financing Cash Flow	4.44M	4.66M	3.96M	4.23M	4.34M

BioLargo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.20, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 26.79 is Positive, neither overbought nor oversold. The STOCH value of 13.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.

BioLargo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$9.72B	6.71	-0.14%	3.11%	2.50%	-46.76%
VHI	58 Neutral	$438.57M	3.77	11.76%	2.09%	7.82%	19465.71%
ORGN	56 Neutral	$127.23M	―	-26.63%	―	-11.91%	-26768.00%
FF	54 Neutral	$169.08M	11.43	-3.29%	6.40%	-33.92%	-58.53%
LXU	51 Neutral	$550.31M	―	-6.51%	―	2.60%	-1506.69%
BLGO	47 Neutral	$52.07M	―	-40.03%	―	22.97%	17.32%
RYAM	45 Neutral	$257.75M	―	-81.36%	―	-4.90%	-458.55%

BioLargo Corporate Events

BioLargo Highlights 2025 Progress and Future Outlook

On July 23, 2025, BioLargo, Inc. provided a mid-year review of its 2025 accomplishments and future outlook. The company highlighted the progress of its subsidiary, Clyra Medical, which is entering the next stage of commercialization with its infection control and wound care products, now available in numerous U.S. healthcare facilities. Additionally, BioLargo’s Cellinity battery technology is gaining traction globally, with a unique ‘sell factories, not batteries’ business model that aims to address the demand for long-duration energy storage. The company has signed several MOUs with prospective partners to build battery factories, indicating a promising financial upside.

BioLargo Approves Proposals at Annual Meeting

At its 2025 annual stockholder meeting on June 19, 2025, BioLargo, Inc. announced the approval of all proposals, including the election of board members and the authorization for a potential reverse stock split. Although the reverse stock split was approved, the board has no immediate plans to implement it, intending to do so only if necessary for uplisting to a national exchange. CEO Dennis Calvert highlighted the company’s strategic positioning and readiness to expand its market reach and attract institutional investors when conditions are favorable.

BioLargo Presents at Webcast Investor Conference

BioLargo, Inc. presented a slide presentation at a webcast investor conference on May 15, 2025. The information shared during this event is not considered filed with the SEC and the company does not have an obligation to update it, although it may choose to do so in the future.